Side effects of the 'Ozempic family': the FDA requires warning about the risk of developing optical neuropathy

The FDA has warned about a potential increased risk of anterior ischemic optic neuropathy (NAION) associated with GLP-1 receptor agonists used for weight loss and diabetes. This follows observational studies indicating a higher incidence of NAION in patients with type 2 diabetes treated with Ozempic and similar medications compared to those on other diabetes treatments. NAION can lead to sudden vision loss and is the second leading cause of blindness due to optic nerve damage. Patients are advised to consult healthcare professionals if they experience symptoms. Similar warnings have been issued in Europe regarding semaglutide, a GLP-1 medication.